DNA Nanostructure-Based Systems for Intelligent Delivery of Therapeutic Oligonucleotides
Hu Q, Wang S, Wang L, Gu H, Fan C. Adv Healthc Mater. 2018 Jan 22. PubMed
Functional Classification and Experimental Dissection of Long Noncoding RNAs
Kopp F, Mendell JT. Cell. 2018 Jan 25;172(3):393-407. PubMed
The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets
Weidle UH, Dickopf S, Hintermair C, Kollmorgen G, Birzele F, Brinkmann U. Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):17-39. PubMed
Life under the Microscope: Single-Molecule Fluorescence Highlights the RNA World
Ray S, Widom JR, Walter NG. Chem Rev. 2018 Jan 24. PubMed
Design of Exon Skipping Oligonucleotides
Presenter: Annemieke Aartsma-Rus, PhD, Leiden University Medical Center Date: 20 February 2018 Description: Antisense-mediated splicing modulation utilizes antisense oligonucleotides (ASOs) to manipulate the splicing by sterically blocking the binding of splicing factors to pre-mRNA transcripts. While in industry often oligo walks are used to ...
Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
Bailey JK, Shen W, Liang XH, Crooke ST. Nucleic Acids Res. 2017 Oct 13;45(18):10649-10671. Dr. Jeffrey Bailey This paper is the latest in a series of publications from Stanley Crooke’s lab at Ionis investigating the interactions between phosphorothioate antisense oligonucleotides and intracellular proteins. ...
Interview with Vadim Y Dudkin, PhD
I first became exposed to oligonucleotide delivery while at Merck upon the acquisition of Sirna in 2006. Part of my work at the time involved glyco
Interview with Hannah Pendergraff, PhD
I became interested in oligo therapeutics when I started working in David Corey’s lab. I joined his group in 2009...
Interview with Keith T. Gagnon, PhD
I was thrown into the world of nucleic acid therapeutics during my postdoc with David Corey. Â My Ph.D. training focused on the...
Interview with Paul Burke, PhD
Paul Burke, PhD Principal, Burke Bioventures LLC How did you become interested in the field of oligonucleotides? I first became interested in
